تصفح Pharmacy Research حسب الموضوع "Metformin"
السجلات المعروضة 1 -- 7 من 7
-
AMP-activated protein kinase as a drug target in chronic kidney disease
( Bentham Science Publishers B.V. , 2018 , Article Review)Background: Chronic kidney disease (CKD) is a condition increasingly affecting millions of individuals worldwide and is ranked as the ninth leading cause of death in the United States. AMP-activated protein kinase (AMPK) ... -
AMPK Activation Attenuates Albumin-induced Alterations in Renal Tubular Cells In Vitro
( Hamad bin Khalifa University Press (HBKU Press) , 2016 , Conference)Background: Chronic kidney disease (CKD) is characterized by progressive decline in renal function; if left untreated, it ultimately results in end-stage renal disease (ESRD), a condition that demands either dialysis or ... -
In vivo and in vitro studies evaluating the chemopreventive effect of metformin on the aryl hydrocarbon receptor-mediated breast carcinogenesis
( Elsevier , 2021 , Article)Metformin (MET) is a clinically used anti-hyperglycemic agent that shows activities against chemically-induced animal models of cancer. A study from our laboratory showed that MET protectes against 7, 12-dimethylbenz[a]anthracene ... -
Metformin Attenuates Albumin-induced Alterations in Renal Tubular Cells In Vitro
( Wiley Periodicals, Inc , 2017 , Article)Proteinuria (albuminuria) plays a crucial role in the etiology of chronic kidney disease (CKD) via alteration of multiple signaling pathways and cellular process in renal cells. The objectives of this study are to investigate ... -
Metformin attenuates V-domain Ig suppressor of T-cell activation through the aryl hydrocarbon receptor pathway in Melanoma: In Vivo and In Vitro Studies
( Elsevier , 2021 , Article)Melanoma is an aggressive skin cancer with a high rate of metastasis to other organs. Recent studies specified the overexpression of V-domain Ig suppressor of T-cell activation (VISTA) and Aryl Hydrocarbon Receptor (AHR) ... -
Nephroprotective Effects of Metformin in Diabetic Nephropathy
( Wiley , 2017 , Article)Metformin, a well-known anti-diabetic agent, is very effective in lowering blood glucose in patients with type 2 diabetes with minimal side-effects. Metformin is also being recommended in the treatment of obesity and ... -
Neratinib and metformin: A novel therapeutic approach against HER2-Positive Breast Cancer
( Elsevier , 2025 , Article)BackgroundHER2-positive breast cancer (BC) is highly aggressive with a poor prognosis. It is driven by HER2 oncoprotein activation/crosstalk with other receptors like EGFR/(HER1), HER3, and HER4, in addition to IGF-1R, ...
